NMPA

HONG KONG, SHANGHAI & FLORHAM PARK, N.J., June 25, 2026 HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) announced that pivotal Phase II registration...

CHENGDU, China, June 2026 C Ray Therapeutics (Chengdu) Co., Ltd. announced that it has officially obtained a Radiopharmaceutical Manufacturing...

SHANGHAI, June 23, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND)...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...

CAMBRIDGE, Massachusetts; ROTTERDAM, Netherlands; SHANGHAI, China, June 10, 2026 Harbour BioMed announced that the National Medical Products Administration (NMPA)...

SAN DIEGO, June 7, 2026 LENZ Therapeutics announced that Everest Medicines has acquired the rights to develop, manufacture, and...

SHANGHAI, China, June 5, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug...

CHENGDU, China, May 29, 2026 Kelun-Biotech has presented pivotal Phase II clinical trial results for its next-generation selective RET...

SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...

BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...